autologous cd4+ t cells genetically modified with a retroviral vector expressing the mazf endoribonuclease gene
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT01787994)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd4+ t cells genetically modified with a retroviral vector expressing the mazf endoribonuclease gene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01787994 | Phase 1 | Dec 1, 2012 | University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1